INX IMCD N.V.

IMCD acquires Trichem to accelerate its growth in the pharmaceutical markets in India

IMCD acquires Trichem to accelerate its growth in the pharmaceutical markets in India

Rotterdam, The Netherlands (26 June 2025) – IMCD N.V. ("IMCD" or "Company"), a global leading partner for the distribution and formulation of speciality chemicals and ingredients, has announced the acquisition of 100% of the shares in Trichem Healthcare Private Limited, Trichem Lifesciences Limited and Chemistry & Health FZ LLC.

Founded in 1998 and headquartered in Mumbai, India, Trichem has built a strong reputation in the healthcare sector, supplying high-quality active pharmaceutical ingredients, pharmaceutical intermediates, and formulation solutions. The company also provides regulatory assistance for customers serving the highly regulated pharmaceutical markets in India.

With 36 employees, Trichem operates across India and the Middle East, generating annual revenue of approximately INR 1.7 billion (ca. EUR 18 million) for the financial year ended 31 March 2025. About 33% of this revenue comes from commission income.

"With India being a major supplier of the world’s generic drugs, this acquisition further enhances our portfolio, in particular with active pharmaceutical ingredients, and reinforces our position in the region’s life-sciences industry," said Narendra Varde, Managing Director of IMCD India. "Additionally, we are excited to welcome Trichem’s talented team, whose deep market expertise and strong industry relationships will be invaluable to IMCD."

Chetan Jain, Founder and Promoter of Trichem Group, added: "IMCD and Trichem share a common vision, strong entrepreneurial spirit, and commitment to building lasting partnerships. I am extremely proud of Trichem’s achievements over the past 27 years. Going forward with IMCD’s global presence, and our strong global principal partnerships, I am confident that this business will deliver immense value to our stakeholders.”

- xxx -

About IMCD

IMCD, based in Rotterdam, The Netherlands, is a leading global partner for the distribution and formulation of speciality chemicals and ingredients. IMCD is an expert solutions provider and adds sustainable value to the supply chain. Every day professionals focus on providing the best service through commercial and operational excellence. The company is mindful of the role they play in creating a better planet for all and formulates with consciousness and executes with care, to address business challenges of tomorrow, in partnership and transparency.

In 2024, with over 5,100 employees, IMCD realised revenues of EUR 4,728 million. IMCD N.V.’s shares are traded at Euronext Amsterdam (symbol: IMCD) and included in the Dutch ESG AEX index, as one of 25 companies within the AEX and AMX indices demonstrating best ESG practices.

For further information, please visit    

Media contact

Muriel Werlé

Corporate Communications Director

4

Investor relations contact

Tosca Holtland

Head of Investor Relations

3

Attachment



EN
26/06/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on IMCD N.V.

IMCD NV: 1 director

A director at IMCD NV bought 1,000 shares at 99.100EUR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showin...

Stefano Toffano
  • Stefano Toffano
ING Helpdesk
  • ING Helpdesk

Benelux Morning Notes

Aedifica: Strong results, guidance reiterated; dsm-firmenich: Symrise 1H25 results; IMCD: Stagnating gross profit leads to disappointing 2Q25 EBITA; JDE Peet's: Full of beans; Just Eat Takeaway: 1H25 results, weak update no impact on takeover; Lotus Bakeries: Peer Mondelez 1Q25 results; Melexis: 2Q25 results, gross margin under pressure; Solvay: 2Q25 in line, subdued outlook no surprise after pre-release; TKH Group: Preview: Under a magnifying glass; Universal Music Group: Spotify 2Q25 ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch